Tobin James P
Known title: DirectorCIK: 0001687559
Tobin James P's purchase track record
How the stock did after each of Tobin James P's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
5
of 5 since September 23, 2021
Stock higher 6 months later
20%
3 months: 60%
Median 6-month return
-14.2%
3 months: +3.7%
Beat the S&P 500
0%
median -29.1% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 4/22/2025 | NEOG | $47K | +5.7% | +24.2% | +27.4% |
| 8/6/2024 | NEOG | $51K | -10.3% | -36.5% | +15.2% |
| 10/12/2023 | NEOG | $46K | +21.3% | -13.2% | +19.5% |
| 7/27/2022 | NEOG | $46K | -46.5% | -14.2% | -0.2% |
| 9/23/2021 | NEOG | $43K | +3.7% | -27.5% | +1.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| NEOG | ▲ Buy | Option Exercise | 1,777 | $11K | 10/27/2025 | View on chart |
| NEOG | ▲ Buy | Option Exercise | 2,071 | $12K | 10/7/2025 | View on chart |
| NEOG | ▲ Buy | Open Market | 10,000 | $47K | 4/22/2025 | View on chart |
| NEOG | ▲ Buy | Option Exercise | 1,776 | $25K | 10/28/2024 | View on chart |
| NEOG | ▲ Buy | Grant | 6,075 | $82K | 10/24/2024 | View on chart |
| NEOG | ▲ Buy | Option Exercise | 2,070 | $31K | 10/7/2024 | View on chart |
| NEOG | ▲ Buy | Option Exercise | 236 | $4K | 10/7/2024 | View on chart |
| NEOG | ▲ Buy | Open Market | 3,000 | $51K | 8/6/2024 | View on chart |
| NEOG | ▲ Buy | Open Market | 3,000 | $46K | 10/12/2023 | View on chart |
| NEOG | ▲ Buy | Open Market | 2,000 | $46K | 7/27/2022 | View on chart |
| NEOG | ▲ Buy | Open Market | 1,000 | $43K | 9/23/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Neogen Corp reports earnings, faces FDA warning, outlines growth plan
Neogen released its 2027 Q1 earnings presentation, highlighting recent revenue trends and upcoming initiatives. The company also disclosed an FDA warning related to a contaminated veterinary product, which may affect short‑term perception. At its recent Investor Day, management outlined a plan to reach a 30% EBITDA margin by 2031 and emphasized growing demand for food‑safety solutions. Analysts continue to note the stock’s recent price movement amid these developments.
Neogen Corp reports earnings, faces FDA warning, outlines growth plan. Neogen released its 2027 Q1 earnings presentation, highlighting recent revenue trends and upcoming initiatives. The company also disclosed an FDA warning related to a contaminated veterinary product, which may affect short‑term perception. At its recent Investor Day, management outlined a plan to reach a 30% EBITDA margin by 2031 and emphasized growing demand for food‑safety solutions. Analysts continue to note the stock’s recent price movement amid these developments.